ArticleScience translational medicine2017
Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 4 pooled it
11.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 4 syntheses or guidelines pooled it, 260 citations in OpenAlex.
- Diagnostic Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-analysis.Cancer research communications · 2022Pooled it
- Extracellular vesicle biomarkers for pancreatic cancer diagnosis: a systematic review and meta-analysis.BMC cancer · 2022Pooled it
- Diagnostic and Prognostic Roles of Thrombospondin-2 in Digestive System Cancers.BioMed research international · 2022Pooled it
- Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.International journal of molecular sciences · 2021Pooled it
- THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.Cancer prevention research (Philadelphia, Pa.) · 2021Trial
- Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer.Bioscience reports · 2019Trial
- Spatial multi-omics uncovers an invasive-desmoplastic cellular community with prognostic and therapeutic implications in pancreatic ductal adenocarcinoma.Advanced biotechnology · 2026Article
- Extracellular vesicle biomarkers in pancreatic ductal adenocarcinoma: from bulk detection to single-extracellular vesicle profiling and endoscopic liquid biopsy.Journal of gastroenterology · 2026Review
- Myofibroblastic CAF and Malignant Ductal Cell Crosstalk Drives Epithelial-Mesenchymal Transition and Progression in Pancreatic Ductal Adenocarcinoma via THBS2-SDC/Integrin Axes.International journal of molecular sciences · 2026Article
- A Clinical Score to Identify Individuals at High Risk of Pancreatic Cancer in the General Population.Diagnostics (Basel, Switzerland) · 2026Article
- Pilot validation of a whole-blood mRNA expression-based diagnostic system for early-stage pancreatic ductal adenocarcinoma: a single-center case-control diagnostic accuracy study.Scientific reports · 2026Article
- Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Engineering a glycosyl-imprinted nanozyme with a dual-ligand Ce-MOF for the selective and sensitive colorimetric sensing of CA19-9.Mikrochimica acta · 2026Article
- Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer.Discover oncology · 2026Review
- Discovery of a Secretory Granule Lumen-Enriched Serum Protein Signature in Resectable Pancreatic Ductal Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Toward Timely Diagnosis of Pancreatic Cancer: Revolutionizing Early Detection Through Genomics, Artificial Intelligence, and Noninvasive Biomarkers.Journal of gastroenterology and hepatology · 2026Review
- Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- The Aging Microenvironment Is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer.Cancer research · 2026Article
- Impaired insulin secretion via the Wnt5a/β-catenin pathway contributes to diabetes development in pancreatic cancer.Experimental & molecular medicine · 2026Article
- Macrophage inhibitory cytokine 1, syncollin and thrombospondin-2 in pancreatic ductal adenocarcinoma and chronic pancreatitis differentiation.Frontiers in oncology · 2026Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 1 country.
Jungsun KimInstitute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center (Tumor Biology Program), Perelman School of Medicine, University of Pennsylvania, 9-131 Smilow Center for Translational Research, 3400 Civic Center Boulevard, Philadelphia, PA 19104-5157, USA.ORCID 0000-0003-2454-8065
William R BamletDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
Ann L ObergDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-2539-9807
Kari G ChaffeeDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-7313-1875
Greg DonahueInstitute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center (Tumor Biology Program), Perelman School of Medicine, University of Pennsylvania, 9-131 Smilow Center for Translational Research, 3400 Civic Center Boulevard, Philadelphia, PA 19104-5157, USA.
Xing-Jun CaoEpigenetics Program, Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-4517-4579
Suresh ChariDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Benjamin A GarciaEpigenetics Program, Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Gloria M PetersenDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
Kenneth S ZaretInstitute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center (Tumor Biology Program), Perelman School of Medicine, University of Pennsylvania, 9-131 Smilow Center for Translational Research, 3400 Civic Center Boulevard, Philadelphia, PA 19104-5157, USA. zaret@upenn.edu.ORCID 0000-0001-8932-3145
Mayo Clinic in Florida · USTranslational Therapeutics (United States) · USUniversity of Pennsylvania · USMayo Clinic in Arizona · US
Funding
VIRAL VECTOR COREP30DK019525 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Patrick Seale · 1986 to 2026
$48.3MTissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7MTRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5MShared Resources Core 2: Quantitative Proteomics CoreP01CA196539 · NCI · ROCKEFELLER UNIVERSITY · PI MUIR, TOM · 2015 to 2024
$17.6MMayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic CancerU01CA210138 · NCI · MAYO CLINIC ROCHESTER · PI Shounak Majumder, Kenneth Zaret · 2016 to 2026
$9.0MTRANS-ACTING FACTORS CAUSING CELL-SPECIFIC GENE CONTROLR01GM036477 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ZARET, KENNETH · 1986 to 2023
$7.7MTrans-acting Factors Causing Cell Specific Gene ControlR37GM036477 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ZARET, KENNETH · 2006 to 2015
$5.4MDeterminants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindredsR01CA208517 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO, LI, HU · 2016 to 2020
$2.9MRole of Vav1 protooncogene in pancreatic cancerP20CA102701 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI PETERSEN, GLORIA M. · 2003 to 2003
$1.5MNCI NIH HHS P01 CA196539NCI NIH HHS P20 CA102701NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA208517NCI NIH HHS U01 CA210138NIDDK NIH HHS P30 DK019525NIDDK NIH HHS P30 DK050306NIGMS NIH HHS R01 GM036477NIGMS NIH HHS R37 GM036477
Abstract
Markers are needed to facilitate early detection of pancreatic ductal adenocarcinoma (PDAC), which is often diagnosed too late for effective therapy. Starting with a PDAC cell reprogramming model that recapitulated the progression of human PDAC, we identified secreted proteins and tested a subset as potential markers of PDAC. We optimized an enzyme-linked immunosorbent assay (ELISA) using plasma samples from patients with various stages of PDAC, from individuals with benign pancreatic disease, and from healthy controls. A phase 1 discovery study (
Indexed as
Early Detection of CancerAdenocarcinomaAgedBiomarkers, TumorCA-19-9 AntigenCarcinoma, Pancreatic DuctalCase-Control StudiesDemographyFemaleHumansMaleMiddle AgedReproducibility of ResultsThrombospondin 2ThrombospondinsBiomarkers, TumorCA-19-9 AntigenThrombospondin 2Thrombospondins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.